CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
Open Access
- 11 January 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-15
Abstract
Agonist antibodies (Ab) directed against costimulatory molecules on the surface of antigen-primed T cells are in various stages of pre-clinical and clinical trials, albeit with limited therapeutic benefit as single agents. The underlying mechanisms of action remain incompletely understood. Here, we demonstrate an inhibitory role of ecto-enzyme CD73 for agonistic anti-4-1BB/CD137 Ab therapy. In particular, anti-4-1BB treatment preferentially drives CD73−effector T cell response for tumor inhibition. Anti-CD73 neutralizing Ab further improves anti-4-1BB therapy associated with enhanced anti-tumor T cell immunity. However, the TGF-β-rich tumor milieu confers resistance to anti-4-1BB therapy by sustaining CD73 expression primarily on infiltrating CD8+T cells across several tumor models. TGF-β blockade results in downregulation of CD73 expression on infiltrating T cells and sensitizes resistant tumors to agonistic anti-4-1BB therapy. Thus, our findings identify a mechanism of action for more effective clinical targeting of 4-1BB or likely other costimulatory molecules.Keywords
This publication has 46 references indexed in Scilit:
- NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificityBritish Journal of Cancer, 2012
- CD73 promotes tumor growth and metastasisOncoImmunology, 2012
- The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasisCancer Immunology, Immunotherapy, 2011
- Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐βEuropean Journal of Immunology, 2011
- CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in miceJournal of Clinical Investigation, 2011
- CD73: A Novel Target for Cancer ImmunotherapyCancer Research, 2010
- CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune SuppressionCancer Research, 2010
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisProceedings of the National Academy of Sciences, 2010
- Adenosine receptors: therapeutic aspects for inflammatory and immune diseasesNature Reviews Drug Discovery, 2008
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006